We limit the study to older men because of the widespread use in the United States of ⍺1-AR antagonists as a treatment for benign prostatic hyperplasia (BPH), a diagnosis clinically unrelated to the respiratory system or immune disorders. The gene discussed is AR; the disease is benign prostatic hyperplasia.